Use of VIP as a prognostic marker of autoimmune diseases

Desarrollado por: IIS del Hospital Universitario de La Princesa

Estado de protección

Spanish patent application (ESP201430364) and PCT Application (PCT/ES2015/070182) with International Search Report completely positive.

Intellectual Property Rights: Spanish patent application (ESP201430364) and PCT Application (PCT/ES2015/070182) with International Search Report completely positive.

Brief Summary: Rheumatoid arthritis (RA) and Spondyloarthritis (Spa) are autommune disorders that can increased mortality. Early  autoimmune disorders that can lead to severe disability and increased mortality. Early intensive immunomodulatory treatment is the best approach to slow progression and change long-term outcome. However, it is important to detect those patients who are destined to have a more benign disease to avoid over-treating them. Probably the only validated prognostic factor in RA is anti-citrullinated protein antibodies (ACPA). There are no validated biomarkers for Spa and other autoimmune disorders.

We have described that having low VIP serum levels is a biomarker of worse clinical course and higher requirements of treatment in patients with early RA and Spa. In the former, the relevance of this new biomarker is that it improves the predictive value of ACPA since detect ACPA negative patients at risk of poor evolution and those with both biomarkers exhibited higher requirements of treatment.

VIP has been involved in the differentiation of Th lymphocytes decreasing the production of proinflammatory mediators and administration of exogenous VIP ameliorates arthritis in murine models. It is likely that those patients who are unable to upregulate their VIP levels when they develop RA, show a worse clinical course.

Estado:
N/A
Tecnología sanitaria:
N/A